Objective: Studies based on deseasonalized vitamin D levels suggest that vitamin D may influence the disease activity in multiple sclerosis (MS), and high doses are suggested as add-on treatment to interferon-␤ (IFN-␤). Seasonal fluctuation of vitamin D varies between individuals, thus the relationship to disease activity should preferentially be studied by repeated and simultaneous vitamin D and MRI measurements from each patient.
The extent of seasonal fluctuation of vitamin D varies between individuals, 17 and the relationship with disease activity should therefore preferentially be studied with repeated assessments in each patient. Notably, vitamin D has been shown to regulate the expression of the MS-associated HLA-DRB1*15 allele, 18 HLA-DRB1 and smoking interact in the risk of MS, 19 further advocating that HLA determines the impact of environmental triggers. We performed a prospective 2-year study of 88 HLA-DR typed patients, before and during treatment with interferon-␤-1a (IFN-␤) (Rebif™, Serono International, Geneva, Switzerland), to examine the relationship between vitamin D and disease activity in relapsing-remitting MS (RRMS). The study comprised 12 MRI scans and 9 vitamin D measurements in each patient.
METHODS Study population and design. This study comprised all patients with RRMS who completed at least 12 months of a 24-month randomized, placebo-controlled trial of -3 fatty acids in MS (the OFAMS study). 20 The original OFAMS study comprised 92 patients with RRMS according to the McDonald criteria, age 18 -58 years, Expanded Disability Status Scale (EDSS) score Յ5 at inclusion, and Ն1 relapse or 1 new T1-weighted gadoliniumenhancing lesion (T1 Gdϩ lesion) or T2-weighted lesion (T2 lesion) on MRI in the year prior to inclusion. All patients were treatment naive, except 3 who had stopped using immunomodulatory drugs (1 IFN-␤, 2 glatiramer acetate) Ͼ6 months before inclusion. During the whole study period, the participants received either -3 fatty acids (Triomar™, Pronova Biocare, Sandefjord, Norway) or placebo (corn oil). From month 6, all participants received subcutaneous injections of IFN-␤ 3 times weekly. None of the treatments contained vitamin D. The participants were not given any particular advice regarding vitamin D supplementation. The inclusion period extended from December 2004 until July 2006. The timing of clinical examinations, MRI, and serum sampling is shown in table 1. The patients were recruited at 13 Norwegian MS centers situated at latitudes 58°-63°north.
Clinical examination. EDSS and relapses were recorded by an experienced study neurologist. A relapse was defined as the appearance of new or worsening of old neurologic symptoms or signs, in the absence of fever, persisting for more than 48 hours and causing objective changes on neurologic examination.
Measurement of 25-hydroxyvitamin D. Serum samples
were stored at Ϫ80°C until analysis. The analyses were performed simultaneously for all samples from each patient. The laboratory technicians were not aware of the clinical or radiologic status of the patients. The 25-hydroxyvitamin D [25(OH)D 3 and 25(OH)D 2 ] was measured by radioimmunoassay (RIA kit, ImmunoDiagnostic Systems) at the Department of Medical Biochemistry, St. Olavs Hospital, Trondheim, Norway. The coefficient of variation was 5.4% and 6.3% at 29 and 112 nmol/L, respectively.
HLA-DRB1 typing. The HLA-DRB1 status was determined by DNA sequencing using SeCore Loc DRB1 SEQ kit (Invitrogen) at the Institute of Immunology, Oslo University Hospital, Rikshospitalet.
MRI. The MRIs were performed according to a standardized protocol comprising T2-weighted and T1-weighted Gdϩ scans using a standard head coil with a 1.5 Tesla MRI unit. Blinded assessments of T1 Gdϩ lesions, T2 lesions, and combined unique activity (CUA; the sum of T1 Gdϩ lesions and new or enlarging T2 lesions) were conducted by 2 experienced neuroradiologists.
Statistics.
A large proportion of the scans did not display new T1 Gdϩ lesions, new T2 lesions, or CUA, and the MRI outcomes were therefore dichotomized as present or absent. Due to repeated measurements of 25(OH)D and MRI in each patient, the association between 25(OH)D levels and MRI outcomes was modeled by a logistic regression model for hierarchical data. 21 The SAS GLIMMIX procedure was used to fit the model with random intercepts for patients and fixed 25(OH)D effects. The association was further adjusted for gender, age, and HLA-DRB1 status. The SAS GLIMMIX procedure works well with unbalanced data; therefore, patients with one or more missing values were not excluded from the analysis. McNemar test for dependent proportions, z test for proportions, and Wilcoxon signed-rank test were used for the comparison of proportion of active MRI scans. t Test was used for the comparison of means. Regression to the mean of MRI outcomes was analyzed by linear regression. The statistical analyses were conducted using Statistical Package for the Social Sciences version 15.0 and SAS version 9.2. The figures were constructed using GraphPad Prism 5.0. Mean values (SEM) are given unless otherwise indicated. Findings with p Ͻ 0.05 were considered significant.
Missing and invalid data. Fourteen (2.7%) and 9 (2.0%) MRI scans were missing during study months 1-6 and 7-24, respectively. One (1.1%) 25(OH)D value was missing at baseline, and 3 (1.1%) and 8 (1.8%) during study months 1-6 and 7-24, respectively. At the account of the half-life of 25(OH)D in serum, 22, 23 we defined the MRI-25(OH)D pairs which were within an interval of 31 days as valid. Thus, 11 MRI-25(OH)D pairs of which the interval exceeded 31 days were excluded. Due to invalid or missing values, 1 patient was excluded during study months 7-24 for the logistic regression analysis, while for the comparison of the proportion of active MRI scans between the highest [25(OH)D max ] and the lowest [25(OH)D min ] level of 25(OH)D, we excluded 1 patient during both study months 1-6 and 7-24, and another patient during study months 7-24. Two (2.3%) EDSS scores were missing at month 24. EDTA blood for HLA-DRB1 typing was missing from 4 patients. Missing values were not replaced.
Standard protocol approvals, registrations, and patient consents. The study was approved by the Regional Committee for Medical and Health Research Ethics in Western Norway (table 3) . When adding DRB1*15 as an explanatory variable in the regression model, the level of significance was somewhat strengthened, whereas the odds ratios remained al- As more patients were included during the winter than during the summer (table e-1), it was important to rule out confounding by a regression to the mean effect. 25 MRI activity during study months 1-6 is shown in table e-2, and did not show any significant or pronounced regression to the mean effect. Thus, the mean proportion of MRI scans with new T1 Gdϩ lesions at study months 1-2 and 5-6 were identical (40%), and only slightly reduced for new T2 lesions (45% to 40%) and CUA (54% to 48%).
To further address whether intraindividual fluctuations in 25(OH)D levels were associated with MRI outcomes, we compared the occurrence of new 
DISCUSSION
The main findings of this study are 1) increasing levels of 25(OH)D are associated with a significant and consistent reduction of active MRI scans in untreated patients with MS, irrespective of their DRB1*15 status, 2) no association between the 25(OH)D levels and MRI activity was observed after initiation of IFN-␤, and 3) the association between 25(OH)D levels and MRI outcomes was mainly confined to patients with pronounced seasonal 25(OH)D fluctuation, and was driven by their high 25(OH)D levels and low radiologic disease activity during the summer. The association between 25(OH)D levels and MRI outcomes, including that DRB1*15 status did not alter the results, concurs with previous findings for relapse rate. 8, 9 We did not find any association between the occurrence of relapses and the mean level of 25(OH)D, possibly due to the limited number of relapses. The only previous prospective study that included MRI parameters did not find any significant correlation between the burden of disease or new or enlarging T2 lesions and 25(OH)D. 7 That study did, however, only comprise 23 patients undergoing a limited number of MRI scans.
Based on the rapid kinetics of immunologic vitamin D effects in vitro and in vivo, 26, 27 we hypothesized that any association with MRI outcomes would appear within 1 month. This concurs with a previous study of relapse rate and estimated 25(OH)D levels, 2 but not with a previous observation of a relationship between 25(OH)D and MRI activity lagged by 2 months. 28 Notably, 25(OH)D levels and disease activity in these studies 2, 28 were measured in different populations, and the results are therefore not directly comparable to those reported here.
Previous studies have used one or few deseasonalized 25(OH)D measurements from each patient to study the relationship with disease activity. 8, 9 The in-traindividual variation in 25(OH)D is largely driven by seasonal fluctuation. 24 As our study mainly addressed intraindividual fluctuations, and because intraindividual fluctuation is equalized by deseasonalization, 25(OH)D levels were not deseasonalized in the main analysis. For this reason, it was not surprising that no or only very weak associations remained after deseasonalization.
The present results extend previous findings [7] [8] [9] by showing a consistent association between seasonal fluctuation of 25(OH)D and MRI outcomes in individual nontreated patients. The difference in disease activity between 25(OH)D max and 25(OH)D min suggests that a beneficial effect of 25(OH)D might be most pronounced when the serum level of 25(OH)D exceeds 100 nmol/L. This corroborates an earlier study showing reduced MS risk in people with 25(OH)D levels in the same magnitude. 29 The main strength of the present study is the prospective design with repeated and paired MRI scans and vitamin D measurements before and during IFN-␤ treatment in clinically well-characterized and DR typed patients. Comparing the MRI outcomes at the highest vs the lowest levels of 25(OH)D limited the possibility of confounding, as the comparison was made within each individual patient. The study also has several limitations, however. First, the observation time prior to immunomodulatory treatment was relatively short. Moreover, the number of patients was rather small, and the statistical power of the subgroup analyses consequently limited. Notably, the skewed inclusion of patients could potentially affect our results through a regression to the mean effect of MRI outcomes. 25 The regression to the mean effect was, however, slight and not significant. Any effect of skewed inclusion is therefore modest. A synergistic effect between vitamin D and IFN-␤ has been suggested in experimental allergic encephalomyelitis, 30 and high-dose vitamin D 3 is currently tested as add-on treatment to IFN-␤ in MS. 31 We did not find any association between 25(OH)D levels and MRI outcomes after initiation of IFN-␤. This may seem surprising, as there is no evidence suggesting that the immunomodulatory effects of vitamin D are counteracted by IFN-␤ or vice versa. A reasonable explanation is that IFN-␤ reduced radiologic disease activity, 32 leaving relatively little left to be reduced. Other explanations, however, cannot be excluded. Interestingly, synthesis of interleukin 10, which may mediate anti-inflammatory effects of vitamin D, 13 showed seasonal variation with high summer levels only in patients treated with IFN-␤. 33 Moreover, an association between seasonal variation in MS relapses and air pollution has been shown at a population level. 34 Relapses were associated with air pollution and airway infections only in IFN-␤ users, and not in untreated patients, 35 suggesting that environmental factors may affect treated and nontreated patients differently.
Importantly, the lack of association between physiologic variation in 25(OH)D levels and radiologic disease activity in IFN-␤-treated patients does not exclude that supraphysiologic levels obtained through pharmacologic intervention may be effective, as suggested by immunologic 12, 13 and radiologic 16 effects in pilot studies. The evidence in favor of vitamin D supplementation in MS is, however, limited. Thus, a recent study comprising 23 patients with MS followed for 6 months suggested a negative effect of high-dose vitamin D 2 on disease activity. 36 The immunomodulatory effects of vitamin D make a causative relation between vitamin D levels and MRI outcomes biologically plausible. 26 Although our results are compatible with a causal relationship, other factors with similar seasonal fluctuation as vitamin D may have confounded our results. Thus, solar ultraviolet radiation has been shown to induce regulatory T cells through mechanisms independent of vitamin D. 37 Moreover, several infections that are more common during the winter than during the summer are also associated with an increased relapse rate. 2, 38 Infec-tions were not recorded in our study. A randomized controlled trial sufficiently powered to capture moderate, but still potentially important effects, is needed to prove a causal relationship between vitamin D levels and disease activity in MS.
